$0.05
(Market cap
$263 Mln
Revenue (TTM)
$168 Mln
P/E Ratio
--
P/B Ratio
6.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.5
-
Debt to Equity
0
-
Book Value
$0.7
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
63,700,187
10 Years Aggregate
CFO
$-784.09 Mln
EBITDA
$-1,029.22 Mln
Net Profit
$-897.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MacroGenics (MGNX)
| 156.5 | 3.3 | -5.7 | 140.1 | -6.5 | -29.5 | -18.0 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
MacroGenics (MGNX)
| -50.5 | -65.9 | 43.4 | -58.2 | -29.8 | 110.1 | -14.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MacroGenics (MGNX)
|
4.1 | 263.1 | 167.7 | -14.6 | -52.3 | -29.6 | -- | 6.1 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout MacroGenics (MGNX)
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a... bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. Read more
-
President, CEO & Director
Dr. Scott Koenig M.D., Ph.D.
-
President, CEO & Director
Dr. Scott Koenig M.D., Ph.D.
-
Headquarters
Rockville, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MacroGenics (MGNX)
What is the current share price of MacroGenics Inc (MGNX) Today?
The share price of MacroGenics Inc (MGNX) is $4.13 (NASDAQ) as of 28-Aug-2026 16:00 EDT. MacroGenics Inc (MGNX) has given a return of -6.48% in the last 3 years.
What is the current PB & PE ratio of MacroGenics Inc (MGNX)?
Since, TTM earnings of MacroGenics Inc (MGNX) is negative, P/E ratio is not available.
The P/B ratio of MacroGenics Inc (MGNX) is 6.08 times as on 28-Aug-2026, a 17 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.36 |
1.83 |
2024 |
-3.04 |
1.75 |
2023 |
-65.77 |
3.90 |
2022 |
-3.43 |
2.90 |
2021 |
-5.14 |
4.10 |
What is the 52 Week High and Low of MacroGenics Inc (MGNX)?
The 52-week high and low of MacroGenics Inc (MGNX) are Rs 5.08 and Rs 1.29 as of 31-Aug-2026.
What is the market cap of MacroGenics Inc (MGNX)?
MacroGenics Inc (MGNX) has a market capitalisation of $ 263 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MacroGenics Inc (MGNX)?
Before investing in MacroGenics Inc (MGNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.